A PHASE IB STUDY OF THE PHARMACOKINETICS, SAFETY AND EFFICACY OF ORALLY ADMINISTERED HQP1351 IN SUBJECTS WITH REFRACTORY CHRONIC MYELOID LEUKEMIA (CML) AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)
MD Anderson Study Status
Ascentage Pharma HQP1351 bioavailable inhibitor
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph+ ALL, who have experienced resistance or intolerance to at least three tyrosine kinase inhibitors (TKIs).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.